Positions

Investigator On

  • A Phase II Study of Durvalumab (MEDI 4736) with Radiotherapy for the adjuvant treatment of Intermediate Risk Head and Neck Squamous Cell Carcinoma  awarded by University of North Carolina at Chapel Hill
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group
  • NRG Oncology Member Institution Clinical Trial Fixed Price Subaward Agreement  awarded by NRG ONCOLOGY FOUNDATION
  • Phase Ib 9cUAB30 in Early Stage Breast Cancer to Evaluate Biologic Effect  awarded by University of Wisconsin-Madison
  • Private Grant  awarded by NOVOCURE, INC.
  • Private Grant  awarded by MERCK SHARP & DOHME CORP
  • RAD 2001 (2012-0825): Phase II/III Randomized Trial of Intensity-Modulated Proton Beam Therapy (IMPT) versus Intensity-Modulated Photon Therapy (IMRT) for the Treatment of Oropharyngeal Cancer of the Head and Neck  awarded by UNIVERSITY OF TEXAS (M.D. ANDERSON CANCER CENTER)
  • TBCRC 038: Diversity in the Tumor Genome and Microenvironment as Drivers of DCIS Progession  awarded by Duke University
  • UAB NRG Oncology Master Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION
  • XUAB 17109-TBCRC 038: Diversity in the Tumor Genome and Microenvironment as Drivers of DCIS Progression  awarded by Johns Hopkins University
  • XUAB2107-A Multi-institutional Phase II Study to Evaluate Efficacy and Safety of TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients with PD-L1+ Metastatic Triple Negative Breast Cancer (TARA)  awarded by HOOSIER CANCER RESEARCH NETWORK
  • Full Name

  • Drexell Boggs